Bone marrow transplantation to mice with an experimental model of tuberculosis

A. A. Isaev; L. E. Pospelov; I. V. Bocharova; V. Ya. Hegert; D. S. Stankov; A. V. Prikhodko; V. G. Avdienko; A. L. Pospelov

doi:10.23868/gc217718

Genes & Cells ›› 2006, Vol. 1 ›› Issue (2) : 51 -54. DOI: 10.23868/gc217718

Original Study Articles

research-article

Bone marrow transplantation to mice with an experimental model of tuberculosis

Author information +

History +

PDF

Abstract

The effectiveness of the use of bone marrow cells (CMC) in the treatment of experimental tuberculosis was investigated. It was shown that transplantation of allogeneic bone marrow cells from AKR mice resistant to tuberculosis to C57BL/6 mice sensitive to tuberculosis and infected with mycobacterium strain H37Rv significantly prolonged the life of infected experimental animals and reduced the number of mycobacteria seeded from organs compared with untreated animals. The study of humoral immunity showed that the introduction of allogeneic bone marrow cells leads to nonspecific polyisotypic stimulation of anti-tuberculosis antibodies, which is important in creating a protective humoral background. There was also a pronounced production of IgG2a antibodies in comparison with the level of IgG1 antibodies during therapy with bone marrow cells, which indicates the presence of a Tb1 response, which is clearly protective in tuberculosis. A high level of IgG2a antibodies correlated with a high level of a specific cellular immune response, assessed by a delayed-type hypersensitivity reaction (HRT).

Keywords

tuberculosis / bone marrow / antibodies / immunity

Cite this article

Download citation ▾

A. A. Isaev, L. E. Pospelov, I. V. Bocharova, V. Ya. Hegert, D. S. Stankov, A. V. Prikhodko, V. G. Avdienko, A. L. Pospelov. Bone marrow transplantation to mice with an experimental model of tuberculosis. Genes & Cells, 2006, 1(2): 51-54 DOI:10.23868/gc217718

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Krishanan A. et al. Durable remission with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105(2): 874-8.

[2]	Lane H.C. et al. Syngenic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with ridovudine in human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 1990; 113: 512.

[3]	Авербах М.М., Мороз А.М.,. Апт А.С., Никоненко В.В. Иммуногенетика инфекционных заболеваний. М., Медицина; 1985.

[4]	Gros P., Skamene E., Forget A. Genetic control of natural resistance of mycobacterium bovis (BCG) in mice. J. Immunol. 1981; 127: 2417-21.

[5]	Schwebach J.R., Casadevall A, Schneerson R. et al. Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo. Infect. Immun. 2001; 69(9): 5671-8.

[6]	Hovav A.H., Fishman Y., Bercovier H. Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine. Infect. Immun. 2005; 73(1): 250-7.

[7]	Wang Q.M., Sun S.H., Hu Z.L. et al. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 2004; 22(27-28): 3622-7.

[8]	Williams A., Reljic R., Naylor I. et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004; 111 (3): 328-33.